Trial Profile
Velcade for Proliferative Lupus Nephritis.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary)
- Indications Lupus nephritis
- Focus Therapeutic Use
- 23 Apr 2012 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov record.
- 19 Aug 2011 Planned end date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
- 23 Aug 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.